Actelion's Tracleer Hangs On, Uptravi Launch Begins

Some good luck and transition in its portfolio has Actelion ahead of analysts' estimates and projecting a strong year for its PAH franchise as it launches its latest product. A delay in generics for its old blockbuster is giving its two newest products time to find their footing.

Europe's largest biotech announced fourth quarter and full year earnings Feb. 9 that turned out to be a pleasant surprise...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapy Areas